CN105560163A - Activated carbon adsorption plug and preparation method thereof - Google Patents
Activated carbon adsorption plug and preparation method thereof Download PDFInfo
- Publication number
- CN105560163A CN105560163A CN201510960479.8A CN201510960479A CN105560163A CN 105560163 A CN105560163 A CN 105560163A CN 201510960479 A CN201510960479 A CN 201510960479A CN 105560163 A CN105560163 A CN 105560163A
- Authority
- CN
- China
- Prior art keywords
- activated carbon
- parts
- carbon adsorption
- preparation
- heating
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 title claims abstract description 62
- 238000001179 sorption measurement Methods 0.000 title claims abstract description 31
- 238000002360 preparation method Methods 0.000 title claims abstract description 10
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims abstract description 19
- 125000005456 glyceride group Chemical group 0.000 claims abstract description 14
- 239000011259 mixed solution Substances 0.000 claims abstract description 8
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 claims abstract description 6
- 229920002125 Sokalan® Polymers 0.000 claims abstract description 6
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims abstract description 6
- 229960001631 carbomer Drugs 0.000 claims abstract description 6
- 238000010438 heat treatment Methods 0.000 claims abstract description 6
- 230000008014 freezing Effects 0.000 claims abstract description 4
- 238000007710 freezing Methods 0.000 claims abstract description 4
- 238000003756 stirring Methods 0.000 claims abstract description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 4
- VMPHSYLJUKZBJJ-UHFFFAOYSA-N trilaurin Chemical compound CCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCC)COC(=O)CCCCCCCCCCC VMPHSYLJUKZBJJ-UHFFFAOYSA-N 0.000 claims description 25
- DUXYWXYOBMKGIN-UHFFFAOYSA-N trimyristin Chemical compound CCCCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCC DUXYWXYOBMKGIN-UHFFFAOYSA-N 0.000 claims description 25
- 239000000203 mixture Substances 0.000 claims description 6
- 229910052799 carbon Inorganic materials 0.000 claims description 5
- 238000000034 method Methods 0.000 claims description 5
- 229920000742 Cotton Polymers 0.000 claims description 4
- 229920003123 carboxymethyl cellulose sodium Polymers 0.000 claims description 4
- 229940063834 carboxymethylcellulose sodium Drugs 0.000 claims description 4
- 238000012423 maintenance Methods 0.000 claims description 3
- 241000894006 Bacteria Species 0.000 abstract description 6
- 206010061218 Inflammation Diseases 0.000 abstract description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 5
- 206010059866 Drug resistance Diseases 0.000 abstract description 4
- 201000010099 disease Diseases 0.000 abstract description 4
- 230000001954 sterilising effect Effects 0.000 abstract description 3
- 241000700605 Viruses Species 0.000 abstract description 2
- 244000052616 bacterial pathogen Species 0.000 abstract description 2
- 230000010261 cell growth Effects 0.000 abstract description 2
- 239000000835 fiber Substances 0.000 abstract description 2
- 238000004659 sterilization and disinfection Methods 0.000 abstract description 2
- 230000017423 tissue regeneration Effects 0.000 abstract description 2
- 238000002156 mixing Methods 0.000 abstract 3
- 239000002250 absorbent Substances 0.000 abstract 1
- 230000002745 absorbent Effects 0.000 abstract 1
- 239000001768 carboxy methyl cellulose Substances 0.000 abstract 1
- 230000035876 healing Effects 0.000 abstract 1
- 230000013632 homeostatic process Effects 0.000 abstract 1
- 230000001737 promoting effect Effects 0.000 abstract 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 abstract 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 abstract 1
- 230000004083 survival effect Effects 0.000 abstract 1
- 238000012360 testing method Methods 0.000 description 11
- 206010046914 Vaginal infection Diseases 0.000 description 8
- 210000001215 vagina Anatomy 0.000 description 8
- 208000004926 Bacterial Vaginosis Diseases 0.000 description 5
- 206010047799 Vulvovaginitis trichomonal Diseases 0.000 description 5
- 239000002131 composite material Substances 0.000 description 5
- 201000008100 Vaginitis Diseases 0.000 description 4
- 208000037009 Vaginitis bacterial Diseases 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 230000003628 erosive effect Effects 0.000 description 4
- 230000004054 inflammatory process Effects 0.000 description 4
- 241000222122 Candida albicans Species 0.000 description 3
- 230000000844 anti-bacterial effect Effects 0.000 description 3
- 230000003071 parasitic effect Effects 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- XWBADQOPXPRKBX-FMIVXFBMSA-N 1-n,1-n-diethyl-4-n-[6-methoxy-2-[(e)-2-(4-nitrophenyl)ethenyl]quinolin-4-yl]pentane-1,4-diamine Chemical compound N=1C2=CC=C(OC)C=C2C(NC(C)CCCN(CC)CC)=CC=1\C=C\C1=CC=C([N+]([O-])=O)C=C1 XWBADQOPXPRKBX-FMIVXFBMSA-N 0.000 description 2
- 206010003693 Atrophic vulvovaginitis Diseases 0.000 description 2
- 206010003694 Atrophy Diseases 0.000 description 2
- 241000186660 Lactobacillus Species 0.000 description 2
- 208000025865 Ulcer Diseases 0.000 description 2
- 201000007096 Vulvovaginal Candidiasis Diseases 0.000 description 2
- 239000003716 antitrichomonal agent Substances 0.000 description 2
- 230000037444 atrophy Effects 0.000 description 2
- 229940095731 candida albicans Drugs 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 229940039696 lactobacillus Drugs 0.000 description 2
- 230000000813 microbial effect Effects 0.000 description 2
- 210000004877 mucosa Anatomy 0.000 description 2
- 201000010808 postmenopausal atrophic vaginitis Diseases 0.000 description 2
- 230000000644 propagated effect Effects 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 231100000397 ulcer Toxicity 0.000 description 2
- 206010006784 Burning sensation Diseases 0.000 description 1
- 206010007134 Candida infections Diseases 0.000 description 1
- GUTLYIVDDKVIGB-OUBTZVSYSA-N Cobalt-60 Chemical compound [60Co] GUTLYIVDDKVIGB-OUBTZVSYSA-N 0.000 description 1
- 206010048768 Dermatosis Diseases 0.000 description 1
- 229920002527 Glycogen Polymers 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- MKYBYDHXWVHEJW-UHFFFAOYSA-N N-[1-oxo-1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propan-2-yl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(C(C)NC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 MKYBYDHXWVHEJW-UHFFFAOYSA-N 0.000 description 1
- 206010033165 Ovarian failure Diseases 0.000 description 1
- 208000030852 Parasitic disease Diseases 0.000 description 1
- 208000031481 Pathologic Constriction Diseases 0.000 description 1
- 208000008350 Pruritus Vulvae Diseases 0.000 description 1
- 206010037651 Pyometra Diseases 0.000 description 1
- 208000037656 Respiratory Sounds Diseases 0.000 description 1
- 241000224526 Trichomonas Species 0.000 description 1
- 206010056530 Vulvovaginal pruritus Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 230000000843 anti-fungal effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 201000003984 candidiasis Diseases 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 210000003756 cervix mucus Anatomy 0.000 description 1
- 229940126678 chinese medicines Drugs 0.000 description 1
- 230000001143 conditioned effect Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 238000004332 deodorization Methods 0.000 description 1
- 239000007938 effervescent tablet Substances 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 229940011871 estrogen Drugs 0.000 description 1
- 239000000262 estrogen Substances 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 229940096919 glycogen Drugs 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 230000023597 hemostasis Effects 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 210000000214 mouth Anatomy 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 201000004535 ovarian dysfunction Diseases 0.000 description 1
- 231100000539 ovarian failure Toxicity 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 206010034754 petechiae Diseases 0.000 description 1
- 201000002765 pyometritis Diseases 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 229910052709 silver Inorganic materials 0.000 description 1
- 239000004332 silver Substances 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 230000008719 thickening Effects 0.000 description 1
- 210000002229 urogenital system Anatomy 0.000 description 1
- 208000002003 vulvitis Diseases 0.000 description 1
- 208000010484 vulvovaginitis Diseases 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/02—Suppositories; Bougies; Bases therefor; Ovules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/44—Elemental carbon, e.g. charcoal, carbon black
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Inorganic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Gynecology & Obstetrics (AREA)
- Urology & Nephrology (AREA)
- Reproductive Health (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention discloses an activated carbon adsorption plug and a preparation method thereof. The preparation method comprises: mixing well 98-102 parts of water and 0.8-1.2 parts of carbomer, heating to 65-75 DEG C, adding 4-7 parts of mixed fatty glyceride, and mixing well to obtain a mixed solution; mixing well 3-5 parts of sodium carboxymethyl cellulose, 6-9 parts of glycerol and 78-82 parts of activated carbon, adding the above mixed solution, stirring to obtain dough, injecting the dough into a mold under pressure, freezing and holding the shape, and taking out; heating for 2.5-5.5 hours at 65-85 DEG C, heating for 0.5-2.5 hours at 110-120 DEG C, and wrapping in medical absorbent gauze. The activated carbon adsorption plug has the advantages of high adsorption speed, high adsorbing capacity and high adsorption quantity, various pathogenic bacteria and viruses are adsorbed into fiber holes, and their survival environment is changed, leading to their death, and thus implementing anti-inflammation, pain relief, homeostasis, odor removal and sterilization, promoting cell growth to quicken tissue regeneration and healing a disease without causing drug resistance in bacteria.
Description
Technical field
The present invention relates to technical field of Chinese medicines, be specifically related to a kind of activated carbon adsorption bolt and preparation method thereof.
Background technology
Vaginitis can be divided into following five kinds: bacterial vaginosis, monilial vaginitis, trichomonal vaginitis, senile vaginitis, infantile vaginitis.
The bacterial vaginosis mainly per vaginam microbial a kind of vaginitis in Gartner, passability relation is propagated.Bacterial vaginosis is that Gartner bacterium, anaerobe etc. increase, and lactobacillus reduces, the disease that intravaginal ecological balanced system changes and causes.Wherein, also there is Gartner bacterium parasitic in healthy women vagina.
Colpitis mycotica or monilial vaginitis and false silk candidiasis (VVC) of vulvovaginal are by the microbial a kind of common multiple vulvovaginal inflammation disease of beads.Candida albicans is conditioned pathogen, have this bacterium parasitic, but bacterium amount is few, does not cause symptom in the Newborn of 10-20% and anemia of pregnant woman's vagina of 30%.Only have when whole body and vagina local immunity ability decline, especially local cells immunity degradation, Candida albicans amount reproduction, just can cause vaginitis symptom.
Trichomonal vaginitis is caused by trichomonacide, and the trichomonacide of parasitic human body has trichomonal vaginitis, Trichomonas hominis and buccalis, parasitizes genitourinary system, intestinal and oral cavity respectively, and relevant with dermatosis is trichomonal vaginitis, causes trichomonal vaginitis.Be a kind of parasitic disease propagated mainly through sexual intercourse, there is infectiousness.
Senile vaginitis is common in postclimacteric elderly woman, and because of ovarian failure, estrogen level reduces, vaginal wall atrophy, mucosa is thinning, and in epithelial cell, glycogen content reduces, intravaginal pH value rises, and local resistance reduces, and pathogenic bacterium are easily invaded breeding and cause inflammation.Cardinal symptom is that vaginal secretions increases and pruritus vulvae, burning sensation.Inspection is shown in that vagina is senile change, epithelial atrophy, and pleat disappears, and epithelium flattens sliding, poor.Vaginal mucosa is congested, has little petechia, sometimes sees shallow table ulcer.If ulcer surface and offside adhesion, during examination per vagina, adhesion can separately be caused bleeding, and can cause stricture of vagina even locking when adhesion is serious, inflammation secretions inadequate drainage can form pyrocolpos even pyometra, and current this situation is rare.
Infantile vaginitis mostly occurs the youngest daughter in 2-9 year, is the commonly encountered diseases of women's infant.Because vaginitis is many with vulvitis, therefore, infant vulvovaginitis is often referred to as.
Be used for the treatment of colpitic medicament base and be originally divided into two large class, medicine for external use and oral medicines.Medicine for external use is mainly divided into lotion class, suppository class and effervescent tablet class.The invention provides a kind of activated carbon adsorption bolt, can anti-bacteria rapidly, simultaneously in use safety, effectively, have no side effect and not easily produce drug resistance.
Summary of the invention
For the deficiencies in the prior art, one of technical problem to be solved by this invention is to provide a kind of activated carbon adsorption bolt.
Two of technical problem to be solved by this invention is to provide a kind of preparation method of activated carbon adsorption bolt.
For achieving the above object, the technology used in the present invention solution is:
A preparation method for activated carbon adsorption bolt, by 98-102 part water, 0.8-1.2 part carbomer mix homogeneously, is heated to 65-75 DEG C, adds 4-7 part mixed fatty glycerides mix homogeneously, obtain mixed solution; 3-5 part Carboxymethyl cellulose sodium, 6-9 part glycerol are mixed homogeneously with 78-82 part active carbon, add above-mentioned mixed solution, stir into dough, mould is injected in pressurization, freezing maintenance shape, takes out; At 65-85 DEG C, heat 2.5-5.5 hour, then at 110-120 DEG C of heating 0.5-2.5 hour, finally wrap up medical absorbent cotton/gauze.
Described mixed fatty glycerides is by myristin, trilaurin, 1,3-lauric acid-3-caprin mixes, the mass ratio of described myristin, trilaurin, 1,3-lauric acid-3-caprin is (1-3): (1-3): (1-3).
Present invention also offers a kind of activated carbon adsorption bolt, adopt said method to be prepared from.
Concrete, in the present invention:
Active carbon, No. CAS: 64365-11-3.
Carbomer, No. CAS: 54182-57-9.
Carboxymethyl cellulose sodium, No. CAS: 9085-26-1.
Glycerol, No. CAS: 56-81-5.
Myristin, No. CAS: 555-45-3.
Trilaurin, No. CAS: 538-24-9.
1,3-lauric acid-3-caprin, No. CAS: 65376-23-0.
It is fast that active carbon in a kind of activated carbon adsorption of the present invention bolt has adsorption rate, absorption affinity is strong, the feature that adsorbance is large, at the thickening power of carbomer, the bonding of modified cellulose sodium and filming function, under the figuration effect of mixing-in fat acid glycerol, formed with the ratio of clinical required NACF bore dia, by various malignant bacteria, viruses adsorption is in fiber holes, change its living environment, make it dead, thus reach antiinflammatory, pain relieving, hemostasis, deodorization, sterilizing, Promote cell's growth accelerates tissue regeneration, the effect of cure diseases, and antibacterial can not be made to produce drug resistance.Activated carbon adsorption bolt of the present invention is well-designed according to female pathology structure, adopt built-in suppository type, be placed in the product that intravaginal is used for the treatment of colpitis, be mainly used in the inflammation such as treatment VVC, nonspecific vaginitis, bacterial vaginosis, do not destroy the normal environment of vagina, do not affect the growth of lactobacillus, have no drug resistance, antibacterial stable, has a broad antifungal spectrum, compliance that is easy to use, comfortable, pollution-free, patient is good.
Detailed description of the invention
Embodiment 1
The preparation method of activated carbon adsorption bolt, by 100g deionized water, 1g carbomer mix homogeneously, is heated to 70 DEG C, adds 6g mixed fatty glycerides mix homogeneously, obtain mixed solution; 4g Carboxymethyl cellulose sodium, 8g glycerol are mixed homogeneously with 80g active carbon, add above-mentioned mixed solution, stir into dough, mould is injected in pressurization, freezing maintenance shape, takes out; Heat 4 hours at 80 DEG C, again 115 DEG C of heating 1 hour, finally wrap up medical absorbent cotton/gauze (article No. adopting Yancheng City Xin Feng medical supplies company limited to produce is the medical absorbent cotton/gauze of YYSB-002), the two aluminum composite membrane bag sealing of dress, through cobalt-60 sterilization.Obtain the activated carbon adsorption bolt of embodiment 1,1.5 grams every.
Described mixed fatty glycerides is mixed by 2g myristin, 2g trilaurin, 2g1,3-lauric acid-3-caprin.
Embodiment 2
Prepare activated carbon adsorption bolt by the method for embodiment 1, difference is only: described mixed fatty glycerides is mixed by 3g myristin, 3g trilaurin.Obtain the activated carbon adsorption bolt of embodiment 2,1.5 grams every.
Embodiment 3
Prepare activated carbon adsorption bolt by the method for embodiment 1, difference is only: described mixed fatty glycerides is mixed by 3g myristin, 3g1,3-lauric acid-3-caprin.Obtain the activated carbon adsorption bolt of embodiment 3,1.5 grams every.
Embodiment 4
Prepare activated carbon adsorption bolt by the method for embodiment 1, difference is only: described mixed fatty glycerides is mixed by 3g trilaurin, 3g1,3-lauric acid-3-caprin.Obtain the activated carbon adsorption bolt of embodiment 4,1.5 grams every.
Test case 1
The activated carbon adsorption bolt obtained to embodiment 1-4 carries out therapeutic effect test, select hospital outpatient age 20-60 year cervical erosion III degree of patient 200, be divided into 4 groups at random, often organize 50, use the activated carbon adsorption bolt that embodiment 1-4 is obtained respectively, every day 1, be positioned over vagina deep before sleeping 8 hours, within 14 days, detect conditions of patients improved condition afterwards.Concrete data are in table 1.
Table 1: conditions of patients tables of data
| Cervical erosion III degree | Cervical erosion II degree | Cervical erosion I degree | Recovery from illness | |
| Embodiment 1 | 1 | 6 | 7 | 36 |
| Embodiment 2 | 2 | 8 | 7 | 33 |
| Embodiment 3 | 1 | 8 | 7 | 34 |
| Embodiment 4 | 1 | 8 | 8 | 33 |
Found out by table 1, comparing embodiment 1 and embodiment 2-4, (mixed fatty glycerides adopts myristin, trilaurin, 1 to embodiment 1,3-lauric acid-3-caprin is composite) therapeutic effect is obviously better than embodiment 2-4 (mixed fatty glycerides adopts myristin, trilaurin, the two is composite arbitrarily in 1,3-lauric acid-3-caprin).
Test case 2
The change of activated carbon adsorption bolt quality index under accelerated test condition that testing example 1-4 obtains.
The activated carbon adsorption bolt that embodiment 1-4 is obtained carries out accelerated test in equal conditions, temperature is 40 ± 2 DEG C, place 6 months in the constant temperature humidity chamber of relative humidity 75 ± 5%, sample respectively once 1st month, the 2nd month, the 3rd month, the 6th the end of month at duration of test, by regulation investigate preparation color, melt become the time limit, afterbody particle, content of nanometer silver, stability result is in Table 2-5.
Table 2: the 1st month accelerated test stability result table
| Color | Melt and become the time limit (min) | Appearance | |
| Embodiment 1 | Milky | 44 | Moist |
| Embodiment 2 | Milky | 49 | Smooth |
| Embodiment 3 | Milky | 46 | Moist |
| Embodiment 4 | Milky | 47 | Moist |
Table 3: the 2nd month accelerated test result table
| Color | Melt and become the time limit (min) | Appearance | |
| Embodiment 1 | Milky | 45 | Moist |
| Embodiment 2 | Milky | 50 | Smooth |
| Embodiment 3 | Milky | 47 | Moist |
| Embodiment 4 | Milky | 48 | Moist |
Table 4: the 3rd month accelerated test result table
| Color | Melt and become the time limit (min) | Appearance | |
| Embodiment 1 | Milky | 45 | Moist |
| Embodiment 2 | Milky | 51 | Smooth |
| Embodiment 3 | Milky | 48 | Moist |
| Embodiment 4 | Milky | 50 | Moist |
Table 5: the 6th month accelerated test result table
| Color | Melt and become the time limit (min) | Appearance | |
| Embodiment 1 | Milky | 45 | Moist |
| Embodiment 2 | Micro-yellow | 53 | Indivedual crackle |
| Embodiment 3 | Milky | 49 | Smooth |
| Embodiment 4 | Milky | 51 | Smooth |
Found out by table 2-5, comparing embodiment 1 and embodiment 2-4, (mixed fatty glycerides adopts myristin, trilaurin, 1 to embodiment 1,3-lauric acid-3-caprin is composite) activated carbon adsorption bolt stability is obviously better than embodiment 2-4 (mixed fatty glycerides adopts myristin, trilaurin, the two is composite arbitrarily in 1,3-lauric acid-3-caprin).
Claims (2)
1. a preparation method for activated carbon adsorption bolt, is characterized in that, by 98-102 part water, 0.8-1.2 part carbomer mix homogeneously, is heated to 65-75 DEG C, adds 4-7 part mixed fatty glycerides mix homogeneously, obtain mixed solution; 3-5 part Carboxymethyl cellulose sodium, 6-9 part glycerol are mixed homogeneously with 78-82 part active carbon, add above-mentioned mixed solution, stir into dough, mould is injected in pressurization, freezing maintenance shape, takes out; At 65-85 DEG C, heat 2.5-5.5 hour, then at 110-120 DEG C of heating 0.5-2.5 hour, finally wrap up medical absorbent cotton/gauze.
Described mixed fatty glycerides is by myristin, trilaurin, 1,3-lauric acid-3-caprin mixes, the mass ratio of described myristin, trilaurin, 1,3-lauric acid-3-caprin is (1-3): (1-3): (1-3).
2. an activated carbon adsorption bolt, is characterized in that, adopts method described in claim 1 to be prepared from.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510960479.8A CN105560163A (en) | 2015-12-18 | 2015-12-18 | Activated carbon adsorption plug and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510960479.8A CN105560163A (en) | 2015-12-18 | 2015-12-18 | Activated carbon adsorption plug and preparation method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN105560163A true CN105560163A (en) | 2016-05-11 |
Family
ID=55871191
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201510960479.8A Withdrawn CN105560163A (en) | 2015-12-18 | 2015-12-18 | Activated carbon adsorption plug and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN105560163A (en) |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101628123A (en) * | 2009-08-20 | 2010-01-20 | 云南蜀云科技有限公司 | Woman hemostatic absorption plug |
| US20130143922A1 (en) * | 2011-12-02 | 2013-06-06 | Nigel H. Greig | Thio compounds |
| CN104840485A (en) * | 2015-04-23 | 2015-08-19 | 西安巨绅医药科技有限公司 | Active carbon suppository for treating cervical erosion, and preparation method thereof |
-
2015
- 2015-12-18 CN CN201510960479.8A patent/CN105560163A/en not_active Withdrawn
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101628123A (en) * | 2009-08-20 | 2010-01-20 | 云南蜀云科技有限公司 | Woman hemostatic absorption plug |
| US20130143922A1 (en) * | 2011-12-02 | 2013-06-06 | Nigel H. Greig | Thio compounds |
| CN104840485A (en) * | 2015-04-23 | 2015-08-19 | 西安巨绅医药科技有限公司 | Active carbon suppository for treating cervical erosion, and preparation method thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2609754C (en) | Compositions of benzoic acid and saccharides for regulating and maintaining bacterial flora and acidity in the vagina | |
| CN103272153B (en) | A kind of antibacterial gel and preparation method thereof | |
| CN102697961B (en) | Gynecological cleaning solution and preparation method thereof | |
| CN105496944A (en) | Chitosan gel and preparation method thereof | |
| CN104840485A (en) | Active carbon suppository for treating cervical erosion, and preparation method thereof | |
| CN105288707B (en) | A kind of antipruritic aerogel dressing and preparation method thereof | |
| JP2013507328A (en) | Compositions containing benzoic acid as an active component in combination with an organic acid preservative, and uses thereof | |
| CN103157095B (en) | Kidney bean phytolectin applications in preparation of human drugs and drug composition thereof | |
| CN101797269B (en) | Physiological balance liquid for adjusting microecology in vaginas of women | |
| CN107648660B (en) | Anti-inflammation antibacterial tampon and preparation method thereof | |
| CN105770239A (en) | External health gel for treating gynecological inflammation | |
| JP2016220674A (en) | Probiotic oral tablet and method for producing the same | |
| CN102038679B (en) | Metronidazole, clotrimazole and chlorhexidine acetate vaginal gel and preparation method thereof | |
| CN112022902A (en) | Preparation method and application of carbon-point modified fluconazole eucalyptus oil microemulsion gel | |
| CN105342983A (en) | Activated carbon adsorption suppository and preparation method thereof | |
| CN105362292A (en) | Medicine composition for treating cervical erosion | |
| CN105560163A (en) | Activated carbon adsorption plug and preparation method thereof | |
| CN105434334A (en) | Active carbon suppository used for treating cervical erosion, and preparation method thereof | |
| CN105520957A (en) | Medicine composition for treating cervical erosion | |
| CN103520262B (en) | A kind of lipid soluble gynecological gel | |
| CN105412001A (en) | Chitosan gel and preparing method thereof | |
| CN105497064A (en) | Activated carbon suppository for treating cervical erosion and preparation method of activated carbon suppository | |
| CN109260426B (en) | External traditional Chinese medicine for eliminating mass, eliminating stagnation and relieving pain and preparation method and application thereof | |
| CN115252738A (en) | Composition with antibacterial, itching relieving and odor eliminating effects, and preparation method and application thereof | |
| CN113662998A (en) | A pharmaceutical composition for treating vaginitis and gynecological inflammation, and its preparation method |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WW01 | Invention patent application withdrawn after publication |
Application publication date: 20160511 |
|
| WW01 | Invention patent application withdrawn after publication |